// App-Quantinova.ai

FRI0170 : THERAPEUTIC ΤARGETS AND QUALITY INDICATORS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), DEFINED ACCORDING TO THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS: DATA FROM THE “ATTIKON“ LUPUS COHORT

Researchers

Presenter

  • K. Havatza

Principal Investigators

  • K. Togia

  • S. Flouda

  • A. Pieta

  • O. Gioti

  • D. Nikolopoulos

  • N. Kapsala

  • A. Ntourou

  • P. Rapsomaniki

  • T. Gerogianni

  • D. Tseronis

  • M. Aggelakos

  • T. Karageorgas

  • P. Katsimpri

  • G. Bertsias

  • K. Thomas

  • D. Boumpas

  • A. Fanouriakis

Medical Centers

  • “Attikon” University Hospital, Rheumatology and Clinical Immunology Unit, Athens, Greece

  • University Hospital of Heraklion, Rheumatology and Clinical Immunology, Athens, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Glucocorticoid

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • GlaxoSmithKline (GSK)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved